Rosalind Advisors
Rosalind Advisors reported 35 stocks worth $309M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are DCTH (17.0%), VSTM (11.0%) and FENC (11.0%). Compared with Q2 2026, the fund opened new positions in REPL, TARA and RCKT, added to VSTM, AQST and MYO, trimmed XERS, VOR and PCVX and sold out of CLDX.
Latest filing: what Rosalind Advisors did in Q3 2026
vs Q2 2026
CLDX$7.4M
Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() DCTH Delcath Sys Inc | $52.7M | 17.0% | 3.3M | No change | 8 of 8 | |
| 2 | ![]() VSTM Verastem Inc | $34.1M | 11.0% | 4.2M | +250K (+6%) | 8 of 8 | |
| 3 | ![]() FENC Fennec Pharmaceuticals Inc | $34M | 11.0% | 3.2M | No change | 8 of 8 | |
| 4 | ![]() XERS Xeris Biopharma Holdings Inc | $24.7M | 8.0% | 2.6M | −326K (−11%) | 8 of 8 | |
| 5 | CYBIN INC | $17.1M | 5.5% | 1.4M | −569K (−29%) | 8 of 8 | |
| 6 | ![]() SVRA Savara Inc | $16.4M | 5.3% | 3.2M | No change | 8 of 8 | |
| 7 | ![]() REPL Replimune Group Inc | $13.2M | 4.3% | 1M | New position | 5 of 8 | |
| 8 | ![]() VOR Vor Biopharma Inc Com New | $11.6M | 3.8% | 609K | −39K (−6%) | 3 of 8 | |
| 9 | ![]() MDWD Mediwound Ltd | $10.3M | 3.3% | 749K | No change | 8 of 8 | |
| 10 | ![]() XFOR X4 Pharmaceuticals Inc | $9.3M | 3.0% | 3.2M | No change | 5 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
![]() CLDX Celldex Therapeutics Inc | $7.4M | 200K |
Options
valued at the underlying shares| Stock | Type | Value | Shares | Change |
|---|---|---|---|---|
![]() XNTK Spdr Series Trust | Put | $925K | 250K | +109,400 |
![]() SPY Spdr S&P 500 ETF TR | Put | $382K | 100K | +100,000 |
![]() VSTM Verastem Inc | Call | $357K | 294K | +293,600 |
![]() QQQ Invesco Qqq TR | Put | $258K | 50K | +50,000 |
![]() PEPG Pepgen Inc | Call | $257K | 413K | +412,700 |
🔒 Free account: see all 11.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Rosalind Advisors 13F FAQ
What does Rosalind Advisors own?
Rosalind Advisors reported 35 stocks worth $309M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are DCTH (17.0%), VSTM (11.0%) and FENC (11.0%). The table above lists every position in the filing (the top 10 without an account).
What did Rosalind Advisors buy and sell in Q3 2026?
Compared with Q2 2026: 7 new positions, 7 added to, 9 trimmed and 1 sold out. New positions include REPL, TARA and RCKT. It sold all of CLDX.
When will Rosalind Advisors file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Rosalind Advisors's portfolio worth?
The Q3 2026 filing reports $309M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.






















